{"id":"mmr-bio-manguinhos","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Parotitis"}]},"_chembl":{"chemblId":"CHEMBL4303683","moleculeType":"Small molecule","molecularWeight":"817.79"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains weakened (attenuated) strains of measles, mumps, and rubella viruses that replicate in vaccinated individuals without causing disease, thereby triggering both humoral (antibody) and cellular immune responses. This immunological priming provides long-term protection against infection with wild-type measles, mumps, and rubella viruses.","oneSentence":"MMR Bio-Manguinhos is a live attenuated vaccine that stimulates immune responses against measles, mumps, and rubella viruses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:48.833Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of measles, mumps, and rubella in children and adults"}]},"trialDetails":[{"nctId":"NCT03148990","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella","status":"COMPLETED","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2018-11-20","conditions":"Rubella, Measles","enrollment":432},{"nctId":"NCT01991899","phase":"PHASE3","title":"Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.","status":"COMPLETED","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2015-02","conditions":"Measles, Mumps, Rubella","enrollment":1560},{"nctId":"NCT01777529","phase":"PHASE4","title":"Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations","status":"COMPLETED","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2012-10","conditions":"Measles, Mumps, Rubella","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MMR GlaxoSmithKline"],"phase":"phase_3","status":"active","brandName":"MMR Bio-Manguinhos","genericName":"MMR Bio-Manguinhos","companyName":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","companyId":"the-immunobiological-technology-institute-bio-manguinhos-oswaldo-cruz-foundation","modality":"Biologic","firstApprovalDate":"","aiSummary":"MMR Bio-Manguinhos is a live attenuated vaccine that stimulates immune responses against measles, mumps, and rubella viruses. Used for Prevention of measles, mumps, and rubella in children and adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}